Evidence map›Paper›PMID 24939885›Full record

Trial reportmBio2014

Recovery of the gut microbiome following fecal microbiota transplantation.

Anna M Seekatz, Johannes Aas, Charles E Gessert, Timothy A Rubin, Daniel M Saman, Johan S Bakken, Vincent B Young

2 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 178 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed, 4 pooled it
19.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02318134 phase2completednot on this mapstarted 2017, after this paper: background citation

Fecal Microbiota Transplantation in SAP(Severe Acute Pancreatitis)Patients With Intestinal Barrier Dysfunction

TypeinterventionalSponsorThe First Affiliated Hospital of Nanchang UniversityRan2017 to 2019Enrolled60ConditionsAcute Pancreatitis, Intestinal Bacteria Flora Disturbance, Intestinal Dysfunction, Fecal Microbiota TransplantationArmsFecal Microbiota Transplantation, normal saline
NCT02318147 phase1unknown statusnot on this mapstarted 2016, after this paper: background citation

Fecal Microbiota Transplantation in SAP(Severe Acute Pancreatitis)Patients With Infectious Complications

TypeinterventionalSponsorThe First Affiliated Hospital of Nanchang UniversityRan2016 to 2018Enrolled60ConditionsAcute Pancreatitis, Fecal Microbiota Transplantation, Bacterial Translocation, Infectious ComplicationsArmsFecal Microbiota Transplantation, The traditional treatment
3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 4 syntheses or guidelines pooled it, 330 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Clostridioides difficile pathogenesis and control.Nature reviews. Microbiology · 2026
    Review
  18. Review
  19. Review
  20. Article

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Anna M SeekatzDepartment of Internal Medicine, Division of Infectious Diseases, Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA;
Johannes AasEssentia Health, Department of Gastroenterology, Duluth, Minnesota, USA;
Charles E GessertEssentia Institute of Rural Health, Duluth, Minnesota, USA;
Timothy A RubinEssentia Health, Department of Gastroenterology, Duluth, Minnesota, USA;
Daniel M SamanEssentia Institute of Rural Health, Duluth, Minnesota, USA;
Johan S BakkenSt. Luke's Hospital, Section of Infectious Diseases, Duluth, Minnesota, USA.
Vincent B YoungDepartment of Internal Medicine, Division of Infectious Diseases, Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA; youngvi@med.umich.edu.
Essentia Health · USUniversity of Michigan–Ann Arbor · USSt. Luke's Hospital · US

Funding

University of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OWYANG, CHUNG · 1986 to 2021
$22.5M
The Interplay Between Host Immunity and Clostridium difficile PathogenesisU19AI090871 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YOUNG, VINCENT B · 2010 to 2014
$7.5M
NIAID NIH HHS U19 AI090871NIAID NIH HHS U19AI090871NIDDK NIH HHS P30 DK034933NIDDK NIH HHS P30DK034933
6 · The paper itself

Abstract

unlabelledClostridium difficile infection is one of the most common health care-associated infections, and up to 40% of patients suffer from recurrence of disease following standard antibiotic therapy. Recently, fecal microbiota transplantation (FMT) has been successfully used to treat recurrent C. difficile infection. It is hypothesized that FMT aids in recovery of a microbiota capable of colonization resistance to C. difficile. However, it is not fully understood how this occurs. Here we investigated changes in the fecal microbiota structure following FMT in patients with recurrent C. difficile infection, and imputed a hypothetical functional profile based on the 16S rRNA profile using a predictive metagenomic tool. Increased relative abundance of Bacteroidetes and decreased abundance of Proteobacteria were observed following FMT. The fecal microbiota of recipients following transplantation was more diverse and more similar to the donor profile than the microbiota prior to transplantation. Additionally, we observed differences in the imputed metagenomic profile. In particular, amino acid transport systems were overrepresented in samples collected prior to transplantation. These results suggest that functional changes accompany microbial structural changes following this therapy. Further identification of the specific community members and functions that promote colonization resistance may aid in the development of improved treatment methods for C. difficile infection. IMPORTANCE: Within the last decade, Clostridium difficile infection has surpassed other bacterial infections to become the leading cause of nosocomial infections. Antibiotic use, which disrupts the gut microbiota and its capability in providing colonization resistance against C. difficile, is a known risk factor in C. difficile infection. In particular, recurrent C. difficile remains difficult to treat with standard antibiotic therapy. Fecal microbiota transplantation (FMT) has provided a successful treatment method for some patients with recurrent C. difficile infection, but its mechanism and long-term effects remain unknown. Our results provide insight into the structural and potential metabolic changes that occur following FMT, which may aid in the development of new treatment methods for C. difficile infection.

Indexed as

Biological TherapyMicrobiotaAdultAgedAged, 80 and overBacteriaClostridioides difficileClostridium InfectionsFecesFemaleGastrointestinal TractHumansMaleMiddle AgedMolecular Sequence DataPhylogeny

Identifiers

PMID24939885
PMCPMC4068257
OpenAlexW2103966018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.